

February 24, 2026

PRIOR AUTHORIZATION UPDATE FOR MARKETPLACE MEDICAL REVIEW GUIDELINE

SUMMARY OF NOTIFICATION

On March 2, 2026, the Infliximab Medical Review Guideline (MRG) will reflect new preferred products. All the following biosimilar products will be preferred:

- Inflectra (Q5103)
- Renflexis (Q5104)
- Avsola (Q5121)

On May 1, 2026, the following updates will be applicable:

- Our Trastuzumab MRG will reflect a single preferred product Trazimera (Q5116)
- Our Pegfilgrastim MRG will reflect a new preferred product Fulphila (Q5108)
- Adekveo (crizanlizumab-tmca, J0791) will be subject to newly established Medical Review Guideline (MRG) criteria

KEY DETAILS

Please find complete details on our [Community Provider Website](#) under the “Prior Authorization Requests: Essential Information & Supporting Clinical Documentation” section.